Genetic alterations of p53 and ras genes in 1,3-butadiene- and 2',3'- dideoxycytidine-induced lymphomas

Cancer Research

Volumn 57, Issue 13, 1997, Pages 2710-2714

  Zhuang, Shi Mei ^a   Cochran, Charles ^b   Goodrow, Tamra ^c   Wiseman, Roger W ^b   Söderkvist, Peter ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BUTADIENE; PROTEIN P53; ZALCITABINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; DOSE RESPONSE; FEMALE; GENE FREQUENCY; GENE MUTATION; LYMPHOMA; MALE; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; BLOTTING, SOUTHERN; BUTADIENES; CARCINOGENS; GENES, P53; GENES, RAS; LYMPHOMA, T-CELL; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; ZALCITABINE;

EID: 0030837447     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Pearce, N., and Bethwaite, P. Increasing incidence of non-Hodgkin's: occupational and environmental factors. Cancer Res., 52 (Suppl.): 5496s-5500s, 1992.
2. Matanoski, G. M., Santos-Burgoa, C., and Schwanz, L. Mortality of a cohort of workers in the styrene-butadiene polymer (SBR) manufacturing industry 1943-1982. Environ. Health Perspect., 86: 107-117, 1990.
3. Divine, B. J. An update on mortality among workers at a butadiene facility: preliminary results. Environ. Health Perspect., 86: 119-128, 1990.
4. IARC. 1,3-butadiene. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 54: 237-285, 1992.
5. Melnick, R. L., Huff, J., Chou, B. J., and Miller, R. A. Carcinogenicity of 1.3-butadiene in C57BL/6 X C3H F1 mice at low exposure concentrations. Cancer Res., 50: 6592-6599, 1990.
6. Starnes, M. C., and Cheng, Y. C. Cellular metabolism of 2′.3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem., 262: 988-991, 1987.
7. Rao, G. N., Collins, B. J., Giles, H. D., Heath, J. E., Foley, J. F., May. R. D., and Buckley L. A. Carcinogenicity of 2′.3′-dideoxycytidine in mice. Cancer Res., 56: 4666-4672, 1996.
8. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
9. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-1689, 1989.
10. Shirasawa, S., Urabe, K., Yanagawa, Y., Toshitani, K., Iwama, T., and Sasazuki, T. p53 gene mutations in colorectal tumors from patients with familial polyposis coli. Cancer Res., 51: 2874-2878, 1991.
11. Malkin, D., Li, F. P., Strong. L. C., Graumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., and Friend, S. H. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (Washington DC), 250: 1233-1238, 1990.
12. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collin, F. S., Weston, A., Modali, R., and Harris, C. C. Mutation of the p53 gene occurs in diverse tumor types. Nature (Lond.), 342: 705-708, 1989.
13. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (Lond.), 358: 857-860, 1992.
14. Yew, R. R., and Berk. A. J. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (Lond.), 357: 82-85, 1992.
15. Levine, A. J. The tumor suppressor genes. Annu. Rev. Biochem., 62: 623-651, 1993.
16. Arrowsmith, C. H., and Morin, P. New insights into p53 function from structural studies. Oncogene. 12: 1379-1385, 1996.
17. Balmain, A., and Brown, K. Oncogene activation in chemical carcinogenesis. Adv. Cancer Res., 51: 147-182, 1988.
18. Guerrero, I., Villasante, A., Corces, V., and Pellicer, A. Activation of a c-K-ras oncogene by somatic mutation in mouse lymphomas induced by gamma radiation. Nature (Lond.), 225: 1159-1162, 1984.
19. Zarbl, H., Sukumar, S., Arthur, A. V., Martin-Zanca, D., and Barbacid. M. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature (Lond.), 315: 382-385, 1985.
20. Neri, A., Knowles, D. M., Greco. A., McCormick, F., and Dalla-Favera, R. Analysis of ras oncogene mutations in human lymphoid malignancies. Proc. Natl. Acad. Sci. USA, 85: 9268-9272, 1988.
21. Newcomb, E. W., Steinberg. J. J., and Pellicer, A. ras oncogenes and phenotypic staging in N-methylnitrosourea- and γ-irradiation-induced thymic lymphomas in C57BL/6J mice. Cancer Res., 48: 5514-5521, 1988.
22. Froment, O., Boivin, S., Barbin, A., Bancel, B., Trepo, C., and Marion, M-J. Mutagenesis of ras proto-oncogene in rat liver tumors induced by vinyl chloride. Cancer Res., 54: 5340-5345, 1994.
23. Ballerini, P., Gaidano, G., Gong, J. Z., Tassi, V., Saglio, G., Knowles. D. M., and Dalla-Favera, R. Multiple genetic lesions in acquired immunodeficiency syndromerelated non-Hodgkin's lymphoma. Blood, 81: 166-176, 1993.
24. Devereux, T. R., Foley, J. F., Maronpot, R. R., Kari. F., and Anderson, M. W. Ras proto-oncogene activation in liver and lung tumors from B6C3F1 mice exposed chronically to methylene chloride. Carcinogenesis (Lond.), 14: 795-801, 1993.
25. Hawley, R. G., Fong, A. Z., Ngan, B. Y., and Hawley, T. S. Hematopoietic transforming potential of activated ras in chimeric mice. Oncogene, 11: 1113-1123, 1995.
26. Zhuang, S-M., Eklund, L. K., Cochran, C., Rao, G. N., Wiseman, R. W., and Soderkvist, P. Allelotype analysis of 2′.3′-dideoxycytidine- and 1,3-butadiene-in-duced lymphomas in B6C3F1 mice. Cancer Res., 56: 3338-3343, 1996.
27. Hegi, M. E., Söderkvist, P., Foley, J. F., Schoonhovcn. R., Swenberg, J. A., Kari. F., Maronpot. R., Anderson. M. W., and Wiseman, R. W. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis (Lond.), 14: 803-810, 1993.
28. Goodrow, T., Reynolds, S., Maronpot, R., and Anderson, M. Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene. Cancer Res., 50: 4818-4823, 1990.
29. Buchberg, A. M., Buchwalter, M. S., and Camper. S. A. Mouse chromosome 11. Mamm. Genome, 2 (Suppl.): S162-S181, 1992.
30. Wiseman, R. W., Cochran, C., Dietrich, W., Lander E. S., and Söderkvist P. Allclotyping of butadiene-induced lung and mammary adenocarcinomas of B6C3F1 mice: frequent losses of heterozygosity in regions homologous to human tumor-suppressor genes. Proc. Natl. Acad. Sci. USA, 91: 3759-3763, 1994.
31. You, M., Candrian, U., Maronpot, R. R., Stoner, G. D., and Anderson, M. W. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc. Natl. Acad. Sci. USA, 86: 3070-3074, 1989.
32. Kumar, R., Sukumar, S., and Barbacid, M. Activation of ras oncogenes preceding the onset of neoplasia. Science (Washington DC), 248: 1101-1104, 1990.
33. Newcomb, E. W., Bayona, W., and Pisharody, S. N-Methylnitrosourea-induced Ki-ras codon 12 mutations: early events in mouse thymic lymphomas. Mol. Carcinog., 13: 89-95, 1995.
34. Bos, J. L., Fearon, E. R., Hamilton, S. R., Verlaan-de Vries, M., van Boom, J. H., van der Eb, A. J., and Vogelstein, B. Prevalence of ras gene mutations in human colorectal cancers. Nature (Lond.), 327: 293-297, 1987.
35. Forrester, K., Almoguera, C., Han, K., Grizzle, W. E., and Perucho, M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature (Lond.), 327: 298-303, 1987.
36. Tabata, T., Fujimori, T., Maeda, S., Yamamoto, M., and Saitoh, Y. The role of ras mutations in pancreatic cancer, precancerous lesions, and chronic pancreatitis. Int. J. Pancreatol., 14: 237-244, 1994.
37. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery. C. A., Jr., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature (Lond.), 356: 215-221, 1992.
38. Harvey, M., Vogel, H., Morris. D., Bradley, A., Bernstein, A., and Donehower, L. A. A mutant p53 transgene accelerates tumor development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet., 9: 305-311, 1995.
39. Brathwaite, O., Bayona, W., and Newcomb, E. W. p53 mutations in C57BL/6J murine thymic lymphomas induced by γ-irradiation and N-methylnitrosourea. Cancer Res., 52: 3791-3795, 1992.
40. Matsushima, A. Y., Cesarman, B., Chadburn, A., and Knoeles, D. M. Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am. J. Pathol., 144: 573-584, 1994.
41. Imamura, J., Miyoshi, I., and Koeffler, H. P. p53 in hematologic malignancies. Blood, 84: 2412-2421, 1994.
42. Du, M., Peng, H., Singh, N., Isaacson, P. G., and Pan. L. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphomas. Blood, 86: 4587-4593, 1995.
43. Sander, C. A., Yano, T., Clark, H. M., Harris. C., Longo, D. L., Jaffe, E. S., and Raffeld, M. p53 mutation is associated with progression in follicular lymphomas. Blood, 82: 1994-2004, 1993.
44. Lo Coco, F., Gaidano, G., Louie, D. C., Offit, K., Chaganti, R. S. K., and Dalla-Favera, R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood, 82: 2289-2295, 1993.
45. Chang, H., Benchimol, S., Minden, M. D., and Messner, H. A. Alterations of p53 and c-myc in the clonal evolution of malignant lymphoma. Blood, 83: 452-459, 1994.
46. Cesarman, E., Chadburn, A., Inghirami, G., Gaidano, G., and Knowles,D. M. Structural and functional analysis of oncogene and tumor suppressor genes in adult T-cell leukemia/lymphoma shows frequent p53 mutations. Blood, 80: 3205-3216, 1992.
47. Farrugia, M. M., Duan, L-J., Reis, M. D., Ngan, B. Y., and Berinstein, N. L. Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-myc and Bcl-2 proto-oncogenes. Blood, 83: 191-198, 1994.